Jumanah Algazaq

Jumanah Algazaq

Auto-generated profile, based on publicly available information

Jumanah Algazaq

Infectious Disease Division, Department of Internal Medicine, Faculty of Medicine, Imam Abdulrahman Bin Faisal University, Dammam & King Fahad Hospital of the University, Al Khobar, Saudi Arabia

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2025 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
MAMarwan Alwazzeh
Marwan Alwazzeh
JAJumanah Algazaq
Jumanah Algazaq
FAFatimah Ali Al-Salem
Fatimah Ali Al-Salem
FAFatimah Alabkari
Fatimah Alabkari
SASara M. Alwarthan
Sara M. Alwarthan
FAFahad Abdulaziz Al-Muhanna
Fahad Abdulaziz Al-Muhanna
Multidrug-resistant Acinetobacter baumannii emerged as a threatening “superbug” with significant morbidity and mortality and limited antimicrobial therapy options. The results of different antibiotic combination studies are heterogeneous and controversial. Further comparative studies are crucial to overcome such difficult-to-treat infections and to improve patient outcomes. This study investigates the mortality and outcomes of colistin versus colistin-based combination therapy for infections caused by Multidrug-resistant Acinetobacter baumannii in critically ill patients. A retrospective observational study was conducted at an academic tertiary hospital in Khobar City, Eastern Province, Saudi Arabia. Patients who fulfilled the inclusion criteria and were admitted from January 1, 2017, to December 31, 2022, were included. The investigated primary outcome was 30-day mortality, while secondary outcomes were one-year all-cause mortality, clinical cure, microbiologic eradication, and recurrence of Acinetobacter infections. Statistical comparisons were employed, and a P-value of ≤ .05 was considered significant. Of the 178 patients who fulfilled the inclusion criteria, 47 received colistin only, and 131 received colistin in combinations (55 with carbapenems, 53 with tigecycline, and 23 with both). The estimated 30-day mortality rate of the study population was 22.5%, with statistically insignificant differences in 30-day mortality rates when the colistin group compared to cumulative colistin-based combination (23.4% vs. 22.1%; difference, 1.3 percentage points; 95% confidence interval [CI], 0.487–2.371; P = 0.858) or subgroups. However, colistin-based combination groups showed better secondary outcomes, with significantly less all-cause mortality and better clinical cure in colistin combination with carbapenems or tigecycline and less Acinetobacter infection recurrence in combination with carbapenems. The study findings demonstrate the benefits of investigated colistin combination options that result in less one-year all-cause mortality, better clinical cure, higher microbiologic response, and less infection recurrence. However, no significant differences were observed regarding 30-day mortality. In addition, the study highlights the limitations of the available antimicrobial options and the crucial need for new effective antimicrobials and more successful combinations.

16 January 2026 in Journal of Infection and Public Health
Verified
Journal Article
Open access
MAMarwan Alwazzeh
Marwan Alwazzeh
AAAmani Alnimr
Amani Alnimr
SASara M. Alwarthan
Sara M. Alwarthan
MAMashael Alhajri
Mashael Alhajri
JAJumanah Algazaq
Jumanah Algazaq
Mohammed Taha Al-HaririMohammed Taha Al-Hariri
Mohammed Taha Al-Hariri
Burkholderia cepacia complex bacteria are intrinsically multidrug-resistant opportunistic pathogens that pose a growing threat in hospital settings, particularly among immunocompromised patients. Despite its clinical significance, data on sporadic Burkholderia cepacia complex infections outside cystic fibrosis populations and hospital outbreaks remain limited. A 22-year retrospective observational cohort study (May 2001-April 2023) was carried out at a tertiary care academic center in the Eastern Province of Saudi Arabia. Adults hospitalized with confirmed Burkholderia cepacia infection and ≥ 72 h of antibiotic therapy were included. Demographics, comorbidities, infection type, microbiological resistance profiles, treatment outcomes, and mortality predictors were analyzed using logistic regression and Kaplan-Meier survival estimates. Of 189 identified cases, 151 patients met the inclusion criteria (mean age 53 ± 21 years; 57.6 % male). The majority of infections were hospital-acquired (84.8 %), with bloodstream infections (33.1 %) and ventilator-associated pneumonia (26.5 %) being the most prevalent. Resistance was high to piperacillin/tazobactam (73.6 %), ceftazidime (58.6 %), levofloxacin (57.4 %), carbapenems (42.0 %), and trimethoprim-sulfamethoxazole (30.3 %). Clinical resolution was achieved in 82.1 %, but bacteriological eradication occurred in only 56.9 %, with a recurrence rate of 17.2 %. Mortality reached 9.9 % at 14 days, 17.2 % at 30 days, and 35.8 % at one year. Independent predictors of 30-day mortality included advanced age, critical care admission, central venous catheter insertion, mechanical ventilation, and resistance to fluoroquinolones or carbapenems. Our findings indicate that Burkholderia cepacia complex infections represent a significant clinical challenge due to antibiotic resistance and elevated mortality rates. The data highlight the importance of improving diagnostic and treatment approaches, as well as implementing effective infection control policies, especially for vulnerable hospitalized populations.
1

23 March 2023 in Pediatric Dermatology
Verified
Journal Article
Closed access
JAJumanah Algazaq
Jumanah Algazaq
MKMini Kamboj
Mini Kamboj
NBN. Esther Babady
N. Esther Babady

1 July 2020 in Gastroenterology
Verified
Journal Article
Open access
JAJumanah N. Algazaq
Jumanah N. Algazaq
SDSaravgunjit Singh Daid
Saravgunjit Singh Daid
NZNajam Zaidi
Najam Zaidi

8 September 2020 in Infectious Diseases in Clinical Practice
Verified
Journal Article
Open access
JAJumanah Algazaq
Jumanah Algazaq
CHCristian Hiraldo-Infante
Cristian Hiraldo-Infante
JMJohn Miskovsky
John Miskovsky
An abstract is unavailable. This article is available as a PDF only.